CME/CE Accredited Session
Sponsored by Industry
Click For Session Details
Session Times Listed in ET
Peter Libby, MD
With the COVID-19 pandemic moving through the country, it is important for clinicians to have the most up-to-date information. Join this session with Dr. Peter Libby to learn about the cardiovascular complications of COVID-19 and how you can help patients facing these issues.
Cardiovascular Specialist, Brigham and Women's Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, MA
Advances and Strategies in Lipid Management to Prevent ASCVD Events
Matthew J. Budoff, MD, FACC | Nathan D. Wong, PhD, FACC, FAHA, FNLA, FASPC
This session will review the recent cardiovascular outcomes trials and their clinical implications in reducing ASCVD events. The expert faculty will also discuss the practical usage of therapies targeting ASCVD event reduction as adjuncts to statin therapy to reduce residual ASCVD risk.
Professor of Medicine, UCLA, Endowed Chair of Preventive Cardiology, Lundquist Institute at Harbor-UCLA, Torrance, CA
Professor and Director, Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, Past President, American Society for Preventive Cardiology and Pacific Lipid Association (Chapter of the NLA)
Supported by Amarin Pharma Inc.
Clinical Considerations in Stroke or Transient Ischemic Attack
Joseph Ghobrial, MD, MSc
• Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA).
• Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population
• Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial
Sponsored by AstraZeneca
Javid Moslehi, MD
The development of cardio-oncology as a clinical field has been driven by improved therapeutics resulting in a dramatic increase in the number of cancer survivors (~17,000,00 in the United States alone) many of whom suffer cardiovascular complications related to their cancer treatments. Both "traditional" and "targeted" therapies can affect the cardiovascular system resulting in hypertension, heart failure, myocarditis, arrhythmias, vascular disease, and thrombosis. While recurrence of cancer is the eventual cause of death in many "cancer survivors", cardiovascular disease is responsible for substantial morbidity and mortality in this population. Thus, effective means of mitigating cardiovascular complications of cancer therapies would have substantial impact on health. Here we will review novel issues in cardio-oncology and will give a broad overview of this emerging field.
Associate Professor of Medicine, Director, Cardio-Oncology Program, Co-Director, Vanderbilt Program for Optimizing Immuno-oNcology Therapy (V-POINT), Vanderbilt School of Medicine, Nashville, TN
The Interconnected Cardio-Renal-Metabolic (CRM) Systems
Stephen A. Brunton, MD, FAAFP, CDCES
The objectives of the program are to:
• Review the interconnected nature of the CRM systems
• Identify the shared risk factors that contribute to the development and progression of clinically comorbid conditions within these systems
• Discuss the impact of coexisting conditions of the CRM systems and the continuum of risk
• Highlight a collaborative care approach for patients who are at risk for or have established disorders of the CRM systems
Executive Director, Primary Care Metabolic Group, Winnsboro, SC
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC